AnaptysBio (NASDAQ:ANAB) Earns “Outperform” Rating from Wedbush

AnaptysBio (NASDAQ:ANAB)‘s stock had its “outperform” rating reaffirmed by analysts at Wedbush in a research report issued on Wednesday,RTT News reports. They presently have a $42.00 price objective on the biotechnology company’s stock. Wedbush’s price objective would indicate a potential upside of 95.44% from the company’s previous close.

ANAB has been the subject of several other reports. Truist Financial boosted their price objective on shares of AnaptysBio from $20.00 to $30.00 and gave the company a “hold” rating in a report on Thursday, August 15th. UBS Group boosted their target price on shares of AnaptysBio from $23.00 to $33.00 and gave the company a “neutral” rating in a research report on Wednesday, October 30th. HC Wainwright restated a “buy” rating and set a $55.00 target price on shares of AnaptysBio in a research report on Thursday, October 31st. Guggenheim boosted their target price on shares of AnaptysBio from $75.00 to $90.00 and gave the company a “buy” rating in a research report on Monday, October 21st. Finally, JPMorgan Chase & Co. boosted their target price on shares of AnaptysBio from $69.00 to $75.00 and gave the company an “overweight” rating in a research report on Wednesday, August 7th. Two analysts have rated the stock with a hold rating and ten have given a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $55.45.

AnaptysBio Price Performance

ANAB opened at $21.49 on Wednesday. The firm has a 50 day moving average price of $33.00 and a 200-day moving average price of $29.83. AnaptysBio has a twelve month low of $13.36 and a twelve month high of $41.31.

AnaptysBio (NASDAQ:ANAB) last released its quarterly earnings data on Tuesday, November 5th. The biotechnology company reported ($1.14) earnings per share for the quarter, beating the consensus estimate of ($1.72) by $0.58. AnaptysBio had a negative net margin of 558.25% and a negative return on equity of 255.68%. The firm had revenue of $30.02 million during the quarter, compared to analysts’ expectations of $7.92 million. Equities research analysts anticipate that AnaptysBio will post -6.84 EPS for the current fiscal year.

Insider Activity at AnaptysBio

In related news, CFO Dennis Mulroy sold 12,220 shares of the firm’s stock in a transaction on Monday, September 16th. The shares were sold at an average price of $39.91, for a total transaction of $487,700.20. Following the completion of the transaction, the chief financial officer now directly owns 4,744 shares of the company’s stock, valued at approximately $189,333.04. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. In other AnaptysBio news, CFO Dennis Mulroy sold 12,220 shares of the stock in a transaction on Monday, September 16th. The shares were sold at an average price of $39.91, for a total transaction of $487,700.20. Following the completion of the transaction, the chief financial officer now owns 4,744 shares in the company, valued at $189,333.04. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Eric J. Loumeau sold 8,720 shares of the stock in a transaction on Monday, September 16th. The shares were sold at an average price of $39.82, for a total transaction of $347,230.40. Following the transaction, the insider now owns 7,020 shares of the company’s stock, valued at $279,536.40. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 22,440 shares of company stock valued at $892,936. Corporate insiders own 33.70% of the company’s stock.

Hedge Funds Weigh In On AnaptysBio

Institutional investors have recently bought and sold shares of the business. Victory Capital Management Inc. lifted its holdings in shares of AnaptysBio by 677.9% in the 3rd quarter. Victory Capital Management Inc. now owns 237,250 shares of the biotechnology company’s stock worth $7,948,000 after acquiring an additional 206,750 shares during the last quarter. GSA Capital Partners LLP bought a new stake in shares of AnaptysBio in the 3rd quarter worth about $574,000. China Universal Asset Management Co. Ltd. lifted its holdings in shares of AnaptysBio by 81.0% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 5,808 shares of the biotechnology company’s stock worth $195,000 after acquiring an additional 2,600 shares during the last quarter. Values First Advisors Inc. bought a new stake in shares of AnaptysBio in the 3rd quarter worth about $49,000. Finally, Assenagon Asset Management S.A. lifted its holdings in shares of AnaptysBio by 55.1% in the 3rd quarter. Assenagon Asset Management S.A. now owns 475,446 shares of the biotechnology company’s stock worth $15,927,000 after acquiring an additional 168,813 shares during the last quarter.

About AnaptysBio

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.